Research Interest:
Pancreatic cancer; Gallbladder/ biliary/ hepatocellular cancers; Colorectal cancer
Selected Publications:
| 1. | Wallace K, Hill EG, Lewin DN, Williamson G, Oppenheimer S, Ford ME, Wargovich MJ, Berger FG, Bolick SW, Thomas MB, Alberg AJ. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control. .24(3):463-71, 2013. PMCID: PMC3574218
View in: PubMed
| | 2. | Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, Camp ER, Esnaola NF. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. ., 2012.
View in: PubMed
| | 3. | Friday B, Lassere Y, Meyers CA, Mita A, Abbruzzese JL, Thomas MB. A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. Anticancer Res. .32(5):1689-96, 2012.
View in: PubMed
| | 4. | Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. .82(2):67-74, 2012.
View in: PubMed
| | 5. | Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. .17(7):1973-83, 2011.
View in: PubMed
| | 6. | Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs. .30(1):316-26, 2010.
View in: PubMed
| | 7. | Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. .28(25):3994-4005, 2010. PMCID: PMC2940397
View in: PubMed
| | 8. | Burak KW, Thomas MB, Zhu AX. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford). .12(5):321-2, 2010. PMCID: PMC2951819
View in: PubMed
| | 9. | Thomas MB. CanLiv: Shining a Light on Cancer's Neglected "Orphans". Gastrointest Cancer Res. .3(3):131-2, 2009. PMCID: PMC2713140
View in: PubMed
| | 10. | Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. .49(5):1563-70, 2009.
View in: PubMed
| | 11. | Thomas MB. Toward improved outcomes in hepatocellular carcinoma: overcoming the challenges of an "orphan" tumor. Gastrointest Cancer Res. .3(2):73, 2009. PMCID: PMC2684725
View in: PubMed
| | 12. | Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. .44 Suppl 19:136-41, 2009.
View in: PubMed
| | 13. | Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. .27(6):843-50, 2009.
View in: PubMed
| | 14. | García P, Manterola C, Araya JC, Villaseca M, Guzmán P, Sanhueza A, Thomas M, Alvarez H, Roa JC. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. .48(1):79-89, 2009.
View in: PubMed
| | 15. | Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. .50(2):334-41, 2008. PMCID: PMC2658718
View in: PubMed
| | 16. | Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. .123(8):1883-91, 2008. PMCID: PMC2673571
View in: PubMed
| | 17. | Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. .15(11):3147-56, 2008.
View in: PubMed
| | 18. | Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. .26(5):445-54, 2008.
View in: PubMed
| | 19. | Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. .134(12):1325-35, 2008.
View in: PubMed
| | 20. | Thomas MB. Targeted therapies for cancer of the gallbladder. Curr Opin Gastroenterol. .24(3):372-6, 2008.
View in: PubMed
| | 21. | Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S, Carraway KL, Irimura T. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer. .44(7):1048-56, 2008.
View in: PubMed
| | 22. | Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. .109(3):335-9, 2008.
View in: PubMed
| | 23. | Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J. .14(2):123-7, 2008.
View in: PubMed
| | 24. | Thomas MB, Lawrence TS. From the guest editors. Hepatocellular carcinoma. Cancer J. .14(2):94, 2008.
View in: PubMed
| | 25. | Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. .15(4):1008-14, 2008.
View in: PubMed
| | 26. | Thomas MB, Davila M, Abbruzzese JL. Stemming the tide of hepatitis B virus related hepatocellular carcinoma? J Clin Oncol. .26(2):172-4, 2008.
View in: PubMed
| | 27. | Thomas MB, Tetzlaff E, Lozano R, Samp L, Butler CE, Gannon C, Hamilton S, Vauthey JN, Abdalla E. Curing hepatocellular carcinomatosis with biologic therapy and surgery: achieving the impossible? J Surg Oncol. .97(1):82-4, 2008.
View in: PubMed
| | 28. | Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. .110(12):2761-7, 2007.
View in: PubMed
| | 29. | Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB. HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res. .1(6):221-7, 2007. PMCID: PMC2631213
View in: PubMed
| | 30. | Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. .107(2):190-3, 2007.
View in: PubMed
| | 31. | Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. .110(5):1059-67, 2007.
View in: PubMed
| | 32. | Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. .107(2):186-9, 2007.
View in: PubMed
| | 33. | Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. .67(8):3794-800, 2007.
View in: PubMed
| | 34. | Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. .61(1):44-51, 2007.
View in: PubMed
| | 35. | Ribero D, Abdalla EK, Thomas MB, Vauthey JN. Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. .6(4):567-79, 2006.
View in: PubMed
| | 36. | Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. .23(31):8093-108, 2005.
View in: PubMed
| | 37. | Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. .23(13):2892-9, 2005.
View in: PubMed
| | 38. | Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN. Advances in the surgical management of liver malignancies. Cancer J. .10(2):74-87, 2004.
View in: PubMed
| | 39. | Shaughnessy L, Chamblin B, McMahon L, Nair A, Thomas MB, Wakefield J, Koentgen F, Ramabhadran R. Novel approaches to models of Alzheimer's disease pathology for drug screening and development. J Mol Neurosci. .24(1):23-32, 2004.
View in: PubMed
| | 40. | Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia. .17(5):990-3, 2003.
View in: PubMed
|
|